Last $4.90 USD
Change Today +0.21 / 4.48%
Volume 1.2M
As of 8:04 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

therapeuticsmd inc (TXMD) Snapshot

Open
$4.70
Previous Close
$4.69
Day High
$5.00
Day Low
$4.58
52 Week High
03/6/14 - $9.01
52 Week Low
04/19/13 - $2.01
Market Cap
710.9M
Average Volume 10 Days
1.9M
EPS TTM
$-0.23
Shares Outstanding
145.1M
EX-Date
06/6/08
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for THERAPEUTICSMD INC (TXMD)

Related News

No related news articles were found.

therapeuticsmd inc (TXMD) Related Businessweek News

No Related Businessweek News Found

therapeuticsmd inc (TXMD) Details

TherapeuticsMD, Inc. operates as a women’s health care product company. The company manufactures and distributes branded and generic prescription prenatal vitamins, as well as over-the-counter vitamins and cosmetics. It offers prenatal vitamins, iron supplements, vitamin D supplements, natural menopause relief products, and cosmetic stretch mark creams under the vitaMedMD brand, as well as duplicate formulations of its prescription prenatal vitamins products under the BocaGreenMD Prena1 name. The company also focuses on conducting the clinical trials for hormone therapy pharmaceutical products that are designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis, and vaginal dryness. TherapeuticsMD markets its products primarily through a direct national sales force to health care providers, as well as directly through its Website. The company was founded in 2008 and is headquartered in Boca Raton, Florida.

69 Employees
Last Reported Date: 03/5/14
Founded in 2008

therapeuticsmd inc (TXMD) Top Compensated Officers

Co-Founder, Chief Executive Officer and Direc...
Total Annual Compensation: $194.3K
President, Secretary and Director
Total Annual Compensation: $181.4K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $184.7K
Chief Strategy Officer and Executive Vice Pre...
Total Annual Compensation: $120.5K
Compensation as of Fiscal Year 2012.

therapeuticsmd inc (TXMD) Key Developments

TherapeuticsMD Announces Launch of Generic Prenatal Multivitamin

TherapeuticsMD has announced the launch of Prena1 Pearl, BocaGreen's generic formulation of vitaMedMD, Inc.'s new prescription prenatal multivitamin, vitaPearl. vitaPearl is a pearl-shaped softgel that is currently the smallest complete prescription prenatal multivitamin and is the first to contain FOLMAX, FePlus, and pur-DHA.

TherapeuticsMD Announces Launch of vitaMedMD's vitaPearl, the Smallest Complete Prescription Prenatal Multivitamin with FOLMAX, FePlus, and Pur-DHA

TherapeuticsMD announced the launch of vitaMedMD's newest prescription prenatal multivitamin, vitaPearl, adding to its successful prenatal line consisting of vitaMedMD One Rx, vitaMedMD Plus Rx, and vitaMedMD RediChew(TM) Rx. vitaPearl is a pearl-shaped softgel that is currently the smallest complete prescription prenatal multivitamin and the first to contain vitaMedMD's proprietary ingredients of FOLMAX(TM) (immediate and modified release folic acid), FePlus(TM) (ferrous fumarate and ferric sodium EDTA), an iron combination containing a chelated iron, and pur-DHA(TM) (docosahexaenoic acid) among its14 vitamins and minerals. vitaPearl offers women who are planning a pregnancy, pregnant, or nursing a complete prenatal multivitamin in one tiny pearl-shaped softgel and offers providers and payors a unique high-value, high-quality prenatal solution.

TherapeuticsMD, Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2013

TherapeuticsMD, Inc. announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2013. For the quarter, the company’s net revenue increased to $2.9 million compared with $1.2 million for the fourth quarter of 2012. Operating loss was $8.0 million against $5.4 million a year ago. Loss before taxes was $8.4 million against $5.7 million a year ago. Net loss was $8.4 million or $0.06 per basic and diluted share against $5.7 million or $0.06 per basic and diluted share a year ago. For the year, the company’s net revenue was $8.8 million compared with $3.8 million for the fourth quarter of 2012. Operating loss was $25.8 million against $16.1 million a year ago. Loss before taxes was $28.4 million against $35.1 million a year ago. Net loss was $28.4 million or $0.22 per basic and diluted share against $35.1 million or $0.38 per basic and diluted share a year ago. Net cash flows used in operating activities was $20.8 million against $12.7 million a year ago. Purchase of property and equipment was $0.04 million against $0.07 million a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TXMD:US $4.90 USD +0.21

TXMD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TXMD.
View Industry Companies
 

Industry Analysis

TXMD

Industry Average

Valuation TXMD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 81.0x
Price/Book 13.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 74.8x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact THERAPEUTICSMD INC, please visit www.therapeuticsmd.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.